Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
Abstract Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which has been suggested as the underlying cause of cognitive impairments. Previous intervention trials investigated the statins’ effects using cognitive outcome measures. However, available outcome measures have led to...
| Autori principali: | , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
Nature Portfolio
2022-08-01
|
| Serie: | Scientific Reports |
| Accesso online: | https://doi.org/10.1038/s41598-022-17873-x |